What question did this study set out to answer?

This analysis aims to evaluate the efficacy and safety of belumosudil for chronic GvHD treatment.

December 8, 2025BloodOpen Access

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows belumosudil improves outcomes in chronic gvhd, indicating a promising new treatment option.

This analysis aims to evaluate the efficacy and safety of belumosudil for chronic GvHD treatment.
Retrospective multicenter study
Included 113 patients from German and Austrian transplant centers
Assessed organ scoring and response via NIH consensus criteria
Best objective response at one month was 36% complete remission
One-year overall survival was 91.5%
Adverse events primarily included infectious complications in 20% of patients

Holtick et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark